News &amp; Updates

Overweight, obesity linked to better survival in kidney cancer

09 Feb 2021 by

Kidney cancer patients with body mass index (BMI) above the normal range appear to have more favourable outcomes than those who are underweight, results of a recent systematic review and meta-analysis have shown.

Overweight, obesity linked to better survival in kidney cancer

$Venetoclax shows promise in relapsed/refractory light-chain amyloidosis$

Venetoclax shows promise in relapsed/refractory light-chain amyloidosis

Venetoclax-containing regimens seem effective for patients with relapsed/refractory light-chain amyloidosis (AL), a recent study has found.

Venetoclax shows promise in relapsed/refractory light-chain amyloidosis

Metformin may protect against biochemical failure in localized prostate cancer

Use of metformin appears to confer a risk reduction in biochemical failure in men with localized prostate cancer treated with radical prostatectomy or radiation therapy, a study has found.

Metformin may protect against biochemical failure in localized prostate cancer

First-line nivolumab plus ipilimumab improves OS in unresectable malignant pleural mesothelioma

08 Feb 2021 by

Nivolumab plus ipilimumab provides significant and clinically meaningful improvements in overall survival (OS) in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM) compared with standard-of-care (SoC) chemotherapy, results of the CheckMate 743 trial have shown.

First-line nivolumab plus ipilimumab improves OS in unresectable malignant pleural mesothelioma

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

08 Feb 2021 by

Adding oxaliplatin to adjuvant fluoropyrimidine improves overall survival (OS) and disease-free survival (DFS) in patients with microsatellite instability (MSI) stage III colon cancer, a pooled analysis of 12 randomized clinical trials has shown.

Adding oxaliplatin to adjuvant fluoropyrimidine ups OS and DFS in MSI stage III colon cancer

Paediatric-onset IBD linked to cancer risk

07 Feb 2021

Patients with paediatric-onset inflammatory bowel disease (IBD) suffer from a greater risk of developing malignancies, reports a new meta-analysis.

Paediatric-onset IBD linked to cancer risk

07 Feb 2021

Reduced TKI dose on par with standard dose for NSCLC

Initiating tyrosine kinase inhibitor (TKI) therapy at a reduced dose appears to result in progression-free survival (PFS) and 15-month survival outcomes comparable to TKI therapy at the Food and Drug Administration (FDA) standard dose, reports a study.

Reduced TKI dose on par with standard dose for NSCLC

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients

A polygenic risk score (PRS) helps identify organ transplant recipients (OTRs) who are at high risk of developing keratinocyte cancers (KCs), which in turn could improve screening and preventive strategies, a new study has found.

Polygenic risk scores estimate keratinocyte cancer risk in organ transplant recipients